Unknown

Dataset Information

0

Adipose mesenchymal stromal cells isolated from type 2 diabetic patients display reduced fibrinolytic activity.


ABSTRACT: Stem cells have been successfully used for the treatment of critical limb ischemia (CLI). We conducted a clinical trial to determine the feasibility of using autologous adipose-derived mesenchymal stromal cells (AdMSCs) for the treatment of CLI. Unexpectedly, two diabetic patients developed peripheral microthrombosis. This adverse effect, which contrasts with the reported antithrombotic properties of MSCs, may stem from the diabetic environment that alters the fibrinolytic activity of AdMSCs, thereby increasing the probability of developing thrombosis. Here, we confirm this premise by demonstrating that diabetic AdMSCs cultured in the presence of blood sera expressed and released higher levels of plasminogen activator inhibitor type 1, reduced levels of tissue plasminogen activator, and lower d-dimer formation compared with nondiabetic AdMSCs. Thus, to establish an appropriate cell therapy for diabetic patients, we recommend including new preclinical safety tests, such as the d-dimer and/or the tissue plasminogen activator-to-plasminogen activator inhibitor type 1 ratio tests, to assess fibrinolytic activity of cells before implantation.

SUBMITTER: Acosta L 

PROVIDER: S-EPMC3837061 | biostudies-literature | 2013 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Adipose mesenchymal stromal cells isolated from type 2 diabetic patients display reduced fibrinolytic activity.

Acosta Lourdes L   Hmadcha Abdelkrim A   Escacena Natalia N   Pérez-Camacho Inmaculada I   de la Cuesta Antonio A   Ruiz-Salmeron Rafael R   Gauthier Benoit R BR   Soria Bernat B  

Diabetes 20130916 12


Stem cells have been successfully used for the treatment of critical limb ischemia (CLI). We conducted a clinical trial to determine the feasibility of using autologous adipose-derived mesenchymal stromal cells (AdMSCs) for the treatment of CLI. Unexpectedly, two diabetic patients developed peripheral microthrombosis. This adverse effect, which contrasts with the reported antithrombotic properties of MSCs, may stem from the diabetic environment that alters the fibrinolytic activity of AdMSCs, th  ...[more]

Similar Datasets

| S-EPMC8533241 | biostudies-literature
2024-06-22 | PXD036116 | Pride
| S-EPMC4653823 | biostudies-literature
| S-EPMC6224797 | biostudies-literature
| S-EPMC4055150 | biostudies-literature
| S-EPMC5081562 | biostudies-literature
| S-EPMC7003792 | biostudies-literature
| S-EPMC9327293 | biostudies-literature
| S-EPMC7727796 | biostudies-literature
| S-EPMC5121630 | biostudies-literature